LUMYKRAS Trademark

Trademark Overview


On Wednesday, October 14, 2020, a trademark application was filed for LUMYKRAS with the United States Patent and Trademark Office. The USPTO has given the LUMYKRAS trademark a serial number of 90253826. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, June 6, 2022. This trademark is owned by Amgen Inc.. The LUMYKRAS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for use in the prevention of amyloidosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, oncological diseases and disorders, tumors, solid and hematological tumors and growths, hematological and hemolytic diseases and disorders, including bone, joint, vertebral column, intestine, colon, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders; pharmaceutical preparations for use in the treatment of amyloidosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders; pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders, amyloidosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders
lumykras

General Information


Serial Number90253826
Word MarkLUMYKRAS
Filing DateWednesday, October 14, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, June 6, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 9, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations for use in the prevention of amyloidosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, oncological diseases and disorders, tumors, solid and hematological tumors and growths, hematological and hemolytic diseases and disorders, including bone, joint, vertebral column, intestine, colon, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders; pharmaceutical preparations for use in the treatment of amyloidosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders; pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders, amyloidosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, December 1, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAmgen Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 913201799

Party NameAmgen Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 913201799

Trademark Events


Event DateEvent Description
Monday, June 6, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, June 6, 2022ABANDONMENT - NO USE STATEMENT FILED
Saturday, September 18, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 16, 2021SOU EXTENSION 1 GRANTED
Thursday, September 16, 2021SOU EXTENSION 1 FILED
Thursday, September 16, 2021TEAS EXTENSION RECEIVED
Tuesday, May 4, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 9, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 9, 2021PUBLISHED FOR OPPOSITION
Wednesday, February 17, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, February 3, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, February 2, 2021EXAMINER'S AMENDMENT ENTERED
Tuesday, February 2, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, February 2, 2021EXAMINERS AMENDMENT E-MAILED
Tuesday, February 2, 2021EXAMINERS AMENDMENT -WRITTEN
Wednesday, January 27, 2021ASSIGNED TO EXAMINER
Tuesday, December 1, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, October 17, 2020NEW APPLICATION ENTERED IN TRAM